Document is current
Any future updates will be listed below
-
Authors
Siddiqui, Bilal A https://orcid.org/0000-0002-6806-1294
Chapin, Brian F
Jindal, Sonali
Duan, Fei
Basu, Sreyashi https://orcid.org/0000-0002-5028-3833
Yadav, Shalini S
Gu, Ai-Di
Espejo, Alexsandra B https://orcid.org/0000-0002-8841-7219
Kinder, Michelle
Pettaway, Curtis A
Ward, John F
Tidwell, Rebecca S S https://orcid.org/0000-0003-3041-8582
Troncoso, Patricia
Corn, Paul G
Logothetis, Christopher J
Knoblauch, Roland
Hutnick, Natalie
Gottardis, Marco
Drake, Charles G
Sharma, Padmanee
Subudhi, Sumit K
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03177460 at ClinicalTrials.govnct03473730 at ClinicalTrials.govDocuments that mention this clinical trial
Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)
https://doi.org/10.1136/jitc-2022-006262
Documents that mention this clinical trial
Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)
https://doi.org/10.1136/jitc-2022-006262
-
Funding
Funding for this research was provided by:
Janssen Research & Development (N/A)
National Cancer Institute (The University of Texas M.D. Anderson Cancer Cente)
Parker Institute for Cancer Immunotherapy (NA)
Genitourinary Cancers Program of the Cancer Center Support Grant (The University of Texas M.D. Anderson Cancer Cente)
V Foundation for Cancer Research (D2018-014)
The University of Texas MD Anderson Cancer Center Prostate Cancer Moon Shot Program (N/A)
- License Information
